Dupilumab for the treatment of asthma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2017.1282458
Abstract: ABSTRACT Introduction: Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. Dupilumab is directed against the α-subunit of the interleukin (IL)-4 receptor and… read more here.
Keywords: asthma dupilumab; dupilumab treatment; severe asthma; dupilumab ... See more keywords